Driving NBRx and Improving AQ: How DeepIntent Outcomes Delivers for Pharma Advertisers

There are more than 20,000 prescription drugs approved for marketing by the Food and Drug Administration (FDA). And yet, they all have one big thing in common: Driving NBRx, or new-to-brand prescriptions, is a shared goal.

Pharma advertisers need fast, transparent, actionable measurement. This provides timely insights and powers the automatic, real-time optimizations that enable them to influence and optimize their healthcare provider (HCP) and patient campaigns through the funnel. Ultimately, they need to answer these questions: Are they reaching the right verified patients and HCPs? Are they meeting in a clinical setting? Are they writing and filling scripts?

The industry’s fastest cross-platform measurement solution based on clinical data, only DeepIntent Outcomes™ offers daily audience quality (AQ) and script lift metrics. These help pharma brands answer those questions and achieve their goals: driving NBRx and other script performance metrics such as total prescriptions (TRx) and new prescriptions (NRx); improving audience quality (AQ); and reaching the right verified patients and healthcare providers (HCPs), all while decreasing their cost-pers.

Driving NBRx and Improving AQ

With patented technology that links real-world clinical data with impression data, Outcomes’ machine learning algorithms automatically optimize campaigns toward AQ and script performance. The algorithms spend three or four weeks “learning” how to best reach the most high-value patients and HCPs, or those most likely to prescribe your brand, ultimately driving NBRx. From there, ongoing machine learning and bid optimization maximize script volume at the lowest possible cost.

Outcomes is currently used across more than 1,200 campaigns by more than 115 brands. One of those brands is an antiviral medication used to treat symptoms of an infectious disease. Outcomes optimizations improved AQ for all audiences, including third-party segments onboarded from industry-leading data providers.

That delivered 865% greater AQ vs. the disease prevalence from the U.S. population. Ads reached patients who were more likely to be condition sufferers, ultimately driving NBRx. The campaign contributed to more than 2,400 incremental NBRx.

To learn more, download Revolutionizing Healthcare Advertising: How DeepIntent Outcomes™ Delivers Exceptional Performance for Leading Pharma Brands, which also includes pharma brands’ success stories such as:

  • Increasing AQ by up to 164% throughout a campaign
  • Driving NBRx by 154% with a combination of connected TV, online video, and display
  • Influencing 27% script lift within a campaign’s first 120 days
  • Growing verified patient reach while reducing cost-per-verified patient (CPVP) by 37%
  • and more!

More Insights

Innovating With Intent 2023- The state of convergent TV
Blog Post
The State of Convergent TV: 3 Takeaways from Our Innovating with Intent Event
In its true form, convergence refers to the shift from analog to digital, something that’s been happening for many years. By 2022, Leichtman Research Group...
Read More
Switching from linear TV to CTV
Blog Post
Three Considerations for Healthcare Marketers Switching from Linear TV to CTV
For decades, traditional or linear TV has dominated the budgets of pharma advertisers. To meet industry recommendations developed decades ago, which call for audience sizes...
Read More
Blog Post
Real-World Outcomes: A Look at the Healthcare Marketing Campaign Metrics Driving Optimization at DeepIntent
Healthcare marketers are looking for deeper, more actionable insights to inform how their campaigns are performing. While clicks and impressions are useful digital metrics for...
Read More
Back to Top